EUCTR2009-016728-29-DE进行中（未招募）不适用
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000(Monofer®) administered by Infusions or Repeated Bolus Injections in Comparison with Oral Iron Sulphate in Subjects with Non-Dialysis Dependent Chronic Kidney Disease and with Renal-Related Anaemia. - P-Monofer-CKD-02
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women, aged more than 18 years.
- •2. Subjects diagnosed with NDD-CKD with MDRD calculated eGFR between 15-59 mL/min.
- •3. Hb < 11.0 g/dL (6.80 mmol/L).
- •4. Either or both of the following iron stores indicators below target [Serum ferritin < 200 ug/l and Transferrin Saturation (TfS) < 20%].
- •5. Life expectancy beyond 12 months by Principal Investigator?s judgement.
- •6. Willingness to participate after informed consent and any authorization as required by local law
- •(e.g. Protected Health Information [PHI] for North America).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 315
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1. Anaemia predominantly caused by factors other than renal impairment or iron deficiency (according to Principal Investigator’s judgment).
- •2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis).
- •3. Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate or any excipients of the study drug.
- •4. Subjects with history of multiple allergies.
- •5. Decompensated liver cirrhosis or active hepatitis (Alanine Aminotransferase (ALT) > 3 times upper normal limit).
- •6. Active acute or chronic infections ((assessed by clinical judgment), supplied with White Blood Cells (WBC) and C-Reactive Protein (CRP)).
- •7. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •8. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product (5 days): Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- •9. Extensive active bleeding necessitating blood transfusion.
- •10. Planned elective surgery during the study.
- •11. Participation in any other clinical study within 3 months prior to screening.
- •12. Known intolerance to oral iron treatment.
- •13. Untreated B12 or folate deficiency.
- •14. I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
- •15. ESA treatment within 8 weeks prior to screening visit.
- •16. Serum ferritin > 500 µg/L.
- •17. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study or interfere with study drug evaluation. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
- •18. Body weight < 30 kilograms.
研究者
相似试验
已完成
3 期
Research Study to demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is non-inferior to oral iron sulphate in reducing renal related anemia in subjects with non-dialysis dependent chronic kidney disease (NDD-CKD), determined as ability to increase Hb.CTRI/2010/091/000417Pharmacosmos AS350
招募中
3 期
To demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is equivalent to IV iron sucrose determined as ability to maintain the iron level to certain limits in patients already on iron therapy with CKD-5D who are on maintenance iron therapyCTRI/2011/05/001740Lars Christensen MD351
进行中（未招募）
不适用
A study to compare Iron Isomaltoside 1000 (Monofer®), as single or repeated injections, with intravenous Iron Sucrose in subjects with Chronic Kidney Disease and who is on Dialysis Therapy (CKD-5D) and have reached stage 5 in their disease.Stage 5 Chronic Kidney DiseaseMedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-023471-26-SEPharmacosmos A/S351
进行中（未招募）
不适用
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with Intravenous Iron Sucrose in Subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).Stage 5 Chronic Kidney Disease on Dialysis Threapy (CKD-5D)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857EUCTR2010-023471-26-PLPharmacosmos A/S350
进行中（未招募）
不适用
Et randomiseret, komparativt, ikke-blindt fase III-forsøg med intravenøst jernisomaltosid 1000 (Monofer®), indgivet som vedligeholdelsesbehandling med enkelte eller gentagne bolusinjektioner sammenlignet med intravenøst jernsukrose hos forsøgspersoner med kronisk nyresygdom i stadie 5, som er i dialyse.EUCTR2010-023471-26-DKPharmacosmos A/S350